ITGA2: Integrin alpha-2
Integrin alpha-2/beta-1 is a receptor for laminin, collagen, collagen C-propeptides, fibronectin and E-cadherin.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ITGA2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Vatelizumab | Phase 2 | Sanofi | Antibody | AntagonistIntegrin alpha-2 antagonist | 0 |
- Abnormality of the skeletal system0.36
- Osteoarthritis, knee0.28
- Osteoarthritis, hip0.26
- Heart disorder0.22
- Osteoarthritis0.21
- Cervical carcinoma0.20
- Hereditary disease0.19
- Platelet-type bleeding disorder 90.19
- Acne0.18
- Sulfite oxidase deficiency due to molybdenum cofactor deficiency type B10.12
- Neoplasm0.12
- Pancreatic ductal adenocarcinoma0.12
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4998, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P17301, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets